Enzymotec unveils $3.5M investment plan
Israeli biotechnology group Enzymotec says that its R&D expenditure for 2007 would reach $3.5 million and will cover several areas of development, including: cognitive health, cardiovascular disease and infant nutrition.
This announcement follows news from the company on a third plant expansion for 2006, the signing of several research contracts with leading health care centers and the publication of its CardiaBeat-McGill study in the December issue of the American Journal of Clinical Nutrition.
The developer and manufacturer of innovative biofunctional ingredients for dietary supplements and functional foods develops and produces novel, lipid-based products among which are: CardiaBeat, SharpPS and SharpPS GOLD for improving cognitive performance and InFat for balanced nutrition for babies and toddlers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze